Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY 518674

Known as: LY-518674, LY518674 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
AIMS Fibrate medications weakly stimulate the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and are… Expand
  • table 1
  • figure 1
Is this relevant?
Review
2010
Review
2010
Metabolic syndrome, diabetes and obesity are frequently associated with hypertriglyceridemia, hypercholesterolemia and low HDL… Expand
  • table 1
  • figure 1
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Expression of ATP binding cassette transporter A1 (ABCA1), a major regulator of high density lipoprotein (HDL) biogenesis, is… Expand
Is this relevant?
2009
2009
Objective—The study of PPAR-α activation on apoA-I production in humans has been limited to fibrates, relatively weak PPAR… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2008
2008
Fibric acid-shaped drugs raise high-density lipoprotein (HDL) cholesterol by upregulating the HDL-related genes through… Expand
Is this relevant?
2008
2008
Objective—The study of PPARactivation on apoA-I production in humans has been limited to fibrates, relatively weak PPARagonists… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
CONTEXT Fibrates are weak agonists of peroxisome proliferator-activated receptor alpha (PPAR-alpha). No trials have reported… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2005
2005
Low high-density lipoprotein-cholesterol (HDL-c) is an important risk factor of coronary artery disease (CAD). Optimum therapy… Expand
Is this relevant?
2005
2005
Low high-density lipoprotein-cholesterol (HDL-c) is an important risk factor of coronary artery disease (CAD). Optimum therapy… Expand
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
Is this relevant?
2003
2003
A new series of hPPARalpha agonists containing a 2,4-dihydro-3H-1,2,4-triazol-3-one (triazolone) core is described leading to the… Expand
Is this relevant?